DOCSLIB.ORG

Download (PDF)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Download (PDF) Supplemental Information Biological and Pharmaceutical Bulletin Promoter Methylation Profiles between Human Lung Adenocarcinoma Multidrug Resistant A549/Cisplatin (A549/DDP) Cells and Its Progenitor A549 Cells Ruiling Guo, Guoming Wu, Haidong Li, Pin Qian, Juan Han, Feng Pan, Wenbi Li, Jin Li, and Fuyun Ji © 2013 The Pharmaceutical Society of Japan Table S1. Gene categories involved in biological functions with hypomethylated promoter identified by MeDIP-ChIP analysis in lung adenocarcinoma MDR A549/DDP cells compared with its progenitor A549 cells Different biological Genes functions transcription factor MYOD1, CDX2, HMX1, THRB, ARNT2, ZNF639, HOXD13, RORA, FOXO3, HOXD10, CITED1, GATA1, activity HOXC6, ZGPAT, HOXC8, ATOH1, FLI1, GATA5, HOXC4, HOXC5, PHTF1, RARB, MYST2, RARG, SIX3, FOXN1, ZHX3, HMG20A, SIX4, NR0B1, SIX6, TRERF1, DDIT3, ASCL1, MSX1, HIF1A, BAZ1B, MLLT10, FOXG1, DPRX, SHOX, ST18, CCRN4L, TFE3, ZNF131, SOX5, TFEB, MYEF2, VENTX, MYBL2, SOX8, ARNT, VDR, DBX2, FOXQ1, MEIS3, HOXA6, LHX2, NKX2-1, TFDP3, LHX6, EWSR1, KLF5, SMAD7, MAFB, SMAD5, NEUROG1, NR4A1, NEUROG3, GSC2, EN2, ESX1, SMAD1, KLF15, ZSCAN1, VAV1, GAS7, USF2, MSL3, SHOX2, DLX2, ZNF215, HOXB2, LASS3, HOXB5, ETS2, LASS2, DLX5, TCF12, BACH2, ZNF18, TBX21, E2F8, PRRX1, ZNF154, CTCF, PAX3, PRRX2, CBFA2T2, FEV, FOS, BARX1, PCGF2, SOX15, NFIL3, RBPJL, FOSL1, ALX1, EGR3, SOX14, FOXJ1, ZNF92, OTX1, ESR1, ZNF142, FOSB, MIXL1, PURA, ZFP37, ZBTB25, ZNF135, HOXC13, KCNH8, ZNF483, IRX4, ZNF367, NFIX, NFYB, ZBTB16, TCF7L1, HIC1, TSC22D1, TSC22D2, REXO4, POU3F2, MYOG, NFATC2, ENO1, HSFX1, TBX3, CEBPD, CREB1, TBX5, TRIM28, LMX1A, VSX1, HIF3A, IRF4, PBX2, ZNF256, MESP2, FOXE3, NFIB plasma membrane part DLC1, CADM3, VAPA, CADM1, AQP5, SYT9, RAB1B, CD52, SYT6, GRIN3B, RCE1, AQP1, AQP2, ZNRF2, SYP, AGTR1, S1PR3, KCNK6, GNG3, HTR1E, PTPRJ, PLD2, EFNB3, GPER, PTPRG, MDGA1, CD40, MYH9, PTPRO, SSTR4, CRHR1, RND2, CRHR2, SSTR2, EGFLAM, PGM5, RHCG, CD34, HTR6, RAB14, PDGFRA, PDGFRB, LAMC2, HAS3, PMP22, HS3ST3B1, DCBLD2, ORAI1, ENPP1, GNAI1, ASZ1, CACNB1, ADRBK1, EPHB1, ITGBL1, DUSP15, GIT1, TRPC4, SMAD7, MAOA, NPY5R, CAMK2N1, NOTCH3, NTRK3, GNGT2, FNBP1, PKP1, EPHA8, RAPSN, NTRK1, NLGN4X, AVPR1B, NTRK2, RHEB, SLC46A1, KCNH1, PCDHA7, TOLLIP, SLC20A2, MYO7A, KCNIP2, GJA4, INSRR, ASGR1, SLC22A4, SYNJ2, HHIP, IL13RA1, KCNG3, SLC22A2, KCNG1, GHR, CTBP2, LYN, CCKBR, RXFP3, MMP16, SIGMAR1, GRM1, LDLRAP1, EPB41L3, SLC26A6, XPR1, DOK7, KCNH6, ADAM17, SGCE, RASD1, PARVA, TF, RAB3C, NPY2R, TFR2, OPRK1, NCF1C, AMPH, SORBS3, SLC4A9, CD24, MICALL2, FLRT2, TRHDE, GPR75, ATRN, FADS2, GJB4, GRIA4, FZD2, SLC16A2, AP2A2, CD19, RAB35, NPHS1, AMOT, RAB39, PTCH2, HTR2C, ENAH, GNA15, GRIK2, GABRB2, TNFSF13, VIPR1, SLC7A6, IL17RB, DMXL2, GPR45, ERAS, MCOLN1, SLC4A3, INSR, SPN, INADL, KCND2, PSD3, SOCS7, STIM1, HLA-B, SLC34A3, ADRM1, TNS1, ARRB1, VAMP5, GPR50, EDA, NEURL2, KIR2DL3, IGSF9, SNTG2, CAV3, SLC38A3, DRD1, FGFR3, DRD5, COPZ1, KEAP1, PCDHAC1, KCNS1, P2RY6, TRO, P2RY1, SCARB1, TRAF7, SLC30A3, PRIMA1, GABRQ, DIXDC1, GABRA2, RAB8B, ADAM23, KCTD19, CD276, CRB3, RAB33A, LAMP1, CORO1A, P2RX1, SLC7A2, SYT13, SLC13A3, HSPD1, SCN8A, ADRA1D, GPR31, CACNA1B, SLC5A3, OPCML, CLDN6, GABBR1, GABBR2, CLTC, LGR5, MBP, GPC4, ACVR1B, SLC1A2, PRMT8, SLC1A6, SNTB1, RHOD, VPS16, ZYX, NRG1, CSK, SV2C, KCNQ1, SLC1A1, DLG1, IRAK1, ANKS1B, PTGER3, LIMK1, ESR1, KTN1, SLC9A3R2, ARHGAP26, CCNL2, GAK, BBS1, OSM, PRKD1, TNFRSF9, SDC1, FOLH1, ULBP3, FAM120A, ARCN1, LCK, CA4, JAM2, TM4SF5, ROM1, CALCR, PRKCZ, FKBP8, TNFRSF25, RHBG, CDH1, TNFRSF4, TPM1, IGF1R, HRH3, RASGRP2, TGM1, INPP5E, SCNN1G, SLC39A4, EHD1, TCIRG1, FLT3, SLC12A5, CD99, FRMPD1, MAL, NUP155, SLC6A7, SCN4B, CHRNA10, F2R, BMPR1A sequence-specific DNA MYOD1, HMX1, CDX2, THRB, HOXD13, RORA, FOXO3, HOXD10, GATA1, HOXC6, ZGPAT, ATOH1, HOXC8, binding FLI1, GATA5, HOXC4, HOXC5, RARB, RARG, SIX3, FOXN1, ZHX3, SIX4, NR0B1, SIX6, DDIT3, ASCL1, HIF1A, MSX1, DPRX, FOXG1, SHOX, TFE3, TFEB, MYEF2, VENTX, ARNT, DBX2, VDR, FOXQ1, MEIS3, HOXA6, LHX2, NKX2-1, LHX6, DNMT3B, EWSR1, MAFB, SMAD7, NR4A1, ESX1, EN2, GSC2, USF2, SHOX2, DLX2, GCM2, HOXB2, LASS3, LASS2, DLX5, ETS2, HOXB5, HSPD1, TCF12, BACH2, PRRX1, CTCF, PRRX2, PAX3, FEV, FOS, BARX1, NFIL3, FOSL1, ALX1, FOXJ1, SOX14, OTX1, ESR1, FOSB, MIXL1, PURA, HOXC13, KCNH8, IRX4, NFIX, NFYB, POU3F2, NFATC2, HSFX1, TBX3, CEBPD, TBX5, CREB1, TRIM28, LMX1A, VSX1, TBL1X, PBX2, FOXE3 transcription regulator CDX2, ZNF639, HOXD13, RORA, HOXD10, SOHLH2, CITED1, MAGED1, ZGPAT, FLI1, SIN3A, WDR77, activity PHTF1, RARB, RARG, ZHX3, HMG20A, MSX1, CAMK4, BAZ1B, MLLT10, FOXG1, DPRX, VGLL2, SHOX, ST18, ZNF382, ZNF131, MYEF2, VENTX, MYBL2, LYL1, LHX2, DNMT3L, NKX2-1, LHX6, DNMT3B, ZNF398, NKRF, KLF5, SMAD7, SMAD5, KLF15, SMAD1, EN2, ZSCAN1, GAS7, USF2, SHOX2, DLX2, ZNF215, TCEB3B, ETS2, DLX5, JAZF1, TCF12, ZNF18, BACH2, TBX21, ZNF154, ZNF345, CCNE1, SIK1, ATF7IP, CTBP2, GMEB2, ZNF142, FOSB, ZFP37, MXD4, ZBTB25, MED7, ZNF135, NAB2, KCNH8, ZNF483, THOC1, POLR2I, ZNF367, ZBTB16, REXO4, TBX3, TBX5, TRIM28, LMX1A, ZNF256, PBX2, FOXE3, TOB1, MYOD1, HMX1, THRB, ARNT2, FOXO3, HOXC6, GATA1, ATOH1, HOXC8, GATA5, HOXC4, HOXC5, ATOH8, MYST2, MYST3, POU2AF1, SIX3, FOXN1, ARID1A, SIX4, NR0B1, SIX6, TRERF1, DDIT3, ELL2, ASCL1, HIF1A, RIPK3, SMARCA1, CCRN4L, TFE3, SOX5, TFEB, UBE2V1, KEAP1, SOX8, ARNT, MED12L, VDR, DBX2, FOXQ1, MEIS3, HOXA6, TFDP3, EWSR1, RFX4, MAFB, NR4A1, NEUROG1, GSC2, ESX1, NEUROG3, VAV1, MSL3, HOXB2, LASS3, LASS2, DYRK1B, HOXB5, DDX54, DNAJB6, E2F8, PRRX1, CTCF, PAX3, PRRX2, PAWR, CBFA2T2, FEV, FOS, BARX1, PCGF2, SOX15, PDE8B, NFIL3, NRG1, FOSL1, RBPJL, ALX1, IRAK1, EGR3, SOX14, FOXJ1, LDB1, ZNF92, OTX1, ESR1, UBE2I, MIXL1, PURA, NCOA3, HOXC13, ZMIZ2, IRX4, NFIX, CDH1, NFYB, TCF7L1, HIC1, TSC22D1, TSC22D2, LBXCOR1, POU3F2, MYOG, NFATC2, GTF3C4, ENO1, NACC2, HSFX1, DTX1, CEBPD, CREB1, VSX1, HIF3A, IRF4, TBL1X, MESP2, NFIB intrinsic to plasma GRIK2, GABRB2, AQP5, TNFSF13, CD52, GRIN3B, RCE1, VIPR1, AQP1, SLC7A6, IL17RB, AGTR1, S1PR3, membrane GPR45, KCNK6, MCOLN1, INSR, SLC4A3, SPN, HTR1E, PTPRJ, KCND2, EFNB3, PTPRG, GPER, MDGA1, STIM1, HLA-B, CD40, MYH9, PTPRO, CRHR1, SSTR4, ADRM1, CRHR2, SSTR2, RHCG, HTR6, PDGFRA, VAMP5, GPR50, PDGFRB, HAS3, EDA, KIR2DL3, HS3ST3B1, DCBLD2, ORAI1, SLC38A3, DRD1, FGFR3, DRD5, EPHB1, PCDHAC1, ITGBL1, KCNS1, P2RY6, TRO, P2RY1, SCARB1, TRAF7, SLC30A3, PRIMA1, GABRQ, TRPC4, ADAM23, KCTD19, NPY5R, NOTCH3, NTRK3, LAMP1, P2RX1, EPHA8, SLC7A2, NTRK1, NTRK2, AVPR1B, NLGN4X, SYT13, SCN8A, ADRA1D, GPR31, SLC5A3, KCNH1, PCDHA7, OPCML, TOLLIP, SLC20A2, GABBR1, GABBR2, GJA4, KCNIP2, LGR5, INSRR, GPC4, ASGR1, ACVR1B, SLC1A6, SLC22A4, ZYX, HHIP, IL13RA1, KCNG3, SLC1A1, KCNQ1, SLC22A2, KCNG1, GHR, IRAK1, PTGER3, LYN, CCKBR, RXFP3, KTN1, MMP16, SIGMAR1, GRM1, CCNL2, PRKD1, OSM, TNFRSF9, SLC26A6, SDC1, FOLH1, XPR1, KCNH6, ADAM17, SGCE, JAM2, TM4SF5, ROM1, CALCR, TNFRSF25, NPY2R, TFR2, OPRK1, RHBG, NCF1C, TNFRSF4, IGF1R, HRH3, CD24, SCNN1G, TCIRG1, FLRT2, TRHDE, FLT3, GPR75, ATRN, FADS2, CD99, MAL, GRIA4, FZD2, SLC16A2, CD19, SLC6A7, NPHS1, SCN4B, PTCH2, CHRNA10, F2R ion transport CALHM1, TSPO, SCN3B, GABRB2, GRIK2, SLC22A15, GRIN3B, AQP1, KCNK7, KCNK6, TPT1, MCOLN1, SLC4A3, FTL, SLC12A8, KCND2, SLC22A23, STIM1, SLC34A3, NNT, KCNT1, RHCG, ORAI1, SLC38A4, SLC38A3, SLC38A2, ENPP1, SLC38A7, CACNB1, ASZ1, SLC38A10, FXYD6, ATP6V0C, VDR, KCNS1, P2RY6, SLC30A3, HCN4, HCN3, GABRQ, HCN1, TRPC4, PRAF2, GABRA2, TRPC6, KCTD19, TST, CORO1A, P2RX1, SLC13A3, SCN8A, CACNA1B, ATP5D, STEAP3, KCNH1, KCNK17, SLC5A3, ATP5E, SLC20A2, ANO1, GJA4, KCNK13, KCNIP2, KCNK10, SLC1A2, SLC1A6, SLC22A4, TRPV4, SLC25A1, ATP5I, KCNG3, SLC1A1, KCNQ1, SLC22A2, KCNG1, TRPM4, PTGER3, TRPM5, TMEM38A, CDK2, ATP6V1F, ATP6V1C2, SLC26A6, SLC26A8, CLIC4, LCK, SLC41A3, KCNH6, KCNH8, STEAP2, KCNH3, TRAPPC10, TF, TFR2, RHBG, FKBP1B, TPCN1, C1QTNF3, FTHL17, SCNN1G, SLC4A9, SLCO3A1, SLC39A4, SLC39A3, KCNE3, TCIRG1, PLP2, SLC12A5, ATP5F1, GRIA4, ZACN, FYN, SCN4B, ABCC8, CHRNA10, F2R integral to plasma GRIK2, GABRB2, AQP5, TNFSF13, CD52, RCE1, GRIN3B, VIPR1, AQP1, SLC7A6, IL17RB, AGTR1, S1PR3, membrane GPR45, KCNK6, MCOLN1, INSR, SLC4A3, SPN, HTR1E, PTPRJ, KCND2, EFNB3, PTPRG, GPER, STIM1, HLA-B, CD40, MYH9, PTPRO, CRHR1, SSTR4, ADRM1, CRHR2, SSTR2, RHCG, HTR6, PDGFRA, VAMP5, GPR50, PDGFRB, HAS3, EDA, KIR2DL3, HS3ST3B1, DCBLD2, ORAI1, SLC38A3, DRD1, FGFR3, DRD5, EPHB1, PCDHAC1, ITGBL1, KCNS1, P2RY6, TRO, P2RY1, SCARB1, SLC30A3, GABRQ, TRPC4, ADAM23, KCTD19, NPY5R, NOTCH3, NTRK3, LAMP1, P2RX1, EPHA8, SLC7A2, NTRK1, NTRK2, AVPR1B, NLGN4X, SYT13, SCN8A, ADRA1D, GPR31, SLC5A3, KCNH1, PCDHA7, OPCML, TOLLIP, SLC20A2, GABBR1, GABBR2, GJA4, KCNIP2, LGR5, INSRR, GPC4, ASGR1, ACVR1B, SLC1A6, SLC22A4, ZYX, HHIP, IL13RA1, KCNG3, SLC1A1, KCNQ1, SLC22A2, KCNG1, GHR, IRAK1, PTGER3, LYN, CCKBR, RXFP3, KTN1, MMP16, SIGMAR1, GRM1, CCNL2, PRKD1, OSM, TNFRSF9, SLC26A6, SDC1, FOLH1, XPR1, KCNH6, ADAM17, SGCE, JAM2, ROM1, TM4SF5, CALCR, TNFRSF25, NPY2R, TFR2, OPRK1, RHBG, NCF1C, TNFRSF4, IGF1R, HRH3, SCNN1G, TCIRG1, FLRT2, TRHDE, FLT3, GPR75, ATRN, FADS2, CD99, MAL, GRIA4, FZD2, SLC16A2, CD19, SLC6A7, NPHS1, SCN4B, PTCH2, CHRNA10, F2R Table S2. Gene categories involved in biological functions with hypermethylated promoter identified by MeDIP-ChIP analysis in lung adenocarcinoma MDR A549/DDP cells compared with its progenitor A549 cells Different biological Genes functions embryonic morphogenesis TWSG1, FGF8, FOXA2, WNT3A, GDF5, HIRA, TGFB3, DSCAML1, ZEB1, ALDH1A2, MACF1, OVOL2, MYO15A, TDGF1, MKKS, IPMK, FRS2, TBX6, RET, SATB2, TBX15, GSC, TGFBR1, SMAD3, SIX2, SKI, SMAD2, CELSR1, SOD1, HOXC10, EYA2, HOXC11, ITGA8, HOXD3, DLD, HOXD4, FOXE1, LRP6, TFAP2A, FOXC1, APAF1, WNT9A, NSD1, MAB21L2, WNT7A, SMARCA4 gastrulation TWSG1, TBX6, FGF8, GSC, FOXA2, WNT3A, HIRA, SMAD3, SMAD2, EYA2, MACF1, DLD, TDGF1, LRP6, MKKS, FOXC1, NSD1, FRS2 .
Load more

Recommended publications
  • 1 Evidence for Gliadin Antibodies As Causative Agents in Schizophrenia
    1 Evidence for gliadin antibodies as causative agents in schizophrenia. C.J.Carter PolygenicPathways, 20 Upper Maze Hill, Saint-Leonard’s on Sea, East Sussex, TN37 0LG [email protected] Tel: 0044 (0)1424 422201 I have no fax Abstract Antibodies to gliadin, a component of gluten, have frequently been reported in schizophrenia patients, and in some cases remission has been noted following the instigation of a gluten free diet. Gliadin is a highly immunogenic protein, and B cell epitopes along its entire immunogenic length are homologous to the products of numerous proteins relevant to schizophrenia (p = 0.012 to 3e-25). These include members of the DISC1 interactome, of glutamate, dopamine and neuregulin signalling networks, and of pathways involved in plasticity, dendritic growth or myelination. Antibodies to gliadin are likely to cross react with these key proteins, as has already been observed with synapsin 1 and calreticulin. Gliadin may thus be a causative agent in schizophrenia, under certain genetic and immunological conditions, producing its effects via antibody mediated knockdown of multiple proteins relevant to the disease process. Because of such homology, an autoimmune response may be sustained by the human antigens that resemble gliadin itself, a scenario supported by many reports of immune activation both in the brain and in lymphocytes in schizophrenia. Gluten free diets and removal of such antibodies may be of therapeutic benefit in certain cases of schizophrenia. 2 Introduction A number of studies from China, Norway, and the USA have reported the presence of gliadin antibodies in schizophrenia 1-5. Gliadin is a component of gluten, intolerance to which is implicated in coeliac disease 6.
    [Show full text]
  • Genetic Associations Between Voltage-Gated Calcium Channels (Vgccs) and Autism Spectrum Disorder (ASD)
    Liao and Li Molecular Brain (2020) 13:96 https://doi.org/10.1186/s13041-020-00634-0 REVIEW Open Access Genetic associations between voltage- gated calcium channels and autism spectrum disorder: a systematic review Xiaoli Liao1,2 and Yamin Li2* Abstract Objectives: The present review systematically summarized existing publications regarding the genetic associations between voltage-gated calcium channels (VGCCs) and autism spectrum disorder (ASD). Methods: A comprehensive literature search was conducted to gather pertinent studies in three online databases. Two authors independently screened the included records based on the selection criteria. Discrepancies in each step were settled through discussions. Results: From 1163 resulting searched articles, 28 were identified for inclusion. The most prominent among the VGCCs variants found in ASD were those falling within loci encoding the α subunits, CACNA1A, CACNA1B, CACN A1C, CACNA1D, CACNA1E, CACNA1F, CACNA1G, CACNA1H, and CACNA1I as well as those of their accessory subunits CACNB2, CACNA2D3, and CACNA2D4. Two signaling pathways, the IP3-Ca2+ pathway and the MAPK pathway, were identified as scaffolds that united genetic lesions into a consensus etiology of ASD. Conclusions: Evidence generated from this review supports the role of VGCC genetic variants in the pathogenesis of ASD, making it a promising therapeutic target. Future research should focus on the specific mechanism that connects VGCC genetic variants to the complex ASD phenotype. Keywords: Autism spectrum disorder, Voltage-gated calcium
    [Show full text]
  • Release Β ATP-Induced IL-1 and Canonical Nicotinic Agonists Inhibit Phosphocholine-Modified Macromolecules
    Phosphocholine-Modified Macromolecules and Canonical Nicotinic Agonists Inhibit ATP-Induced IL-1β Release This information is current as Andreas Hecker, Mira Küllmar, Sigrid Wilker, Katrin of September 24, 2021. Richter, Anna Zakrzewicz, Srebrena Atanasova, Verena Mathes, Thomas Timm, Sabrina Lerner, Jochen Klein, Andreas Kaufmann, Stefan Bauer, Winfried Padberg, Wolfgang Kummer, Sabina Janciauskiene, Martin Fronius, Elke K. H. Schweda, Günter Lochnit and Veronika Grau Downloaded from J Immunol 2015; 195:2325-2334; Prepublished online 22 July 2015; doi: 10.4049/jimmunol.1400974 http://www.jimmunol.org/content/195/5/2325 http://www.jimmunol.org/ Supplementary http://www.jimmunol.org/content/suppl/2015/07/22/jimmunol.140097 Material 4.DCSupplemental References This article cites 42 articles, 11 of which you can access for free at: http://www.jimmunol.org/content/195/5/2325.full#ref-list-1 by guest on September 24, 2021 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2015 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606.
    [Show full text]
  • The Mineralocorticoid Receptor Leads to Increased Expression of EGFR
    www.nature.com/scientificreports OPEN The mineralocorticoid receptor leads to increased expression of EGFR and T‑type calcium channels that support HL‑1 cell hypertrophy Katharina Stroedecke1,2, Sandra Meinel1,2, Fritz Markwardt1, Udo Kloeckner1, Nicole Straetz1, Katja Quarch1, Barbara Schreier1, Michael Kopf1, Michael Gekle1 & Claudia Grossmann1* The EGF receptor (EGFR) has been extensively studied in tumor biology and recently a role in cardiovascular pathophysiology was suggested. The mineralocorticoid receptor (MR) is an important efector of the renin–angiotensin–aldosterone‑system and elicits pathophysiological efects in the cardiovascular system; however, the underlying molecular mechanisms are unclear. Our aim was to investigate the importance of EGFR for MR‑mediated cardiovascular pathophysiology because MR is known to induce EGFR expression. We identifed a SNP within the EGFR promoter that modulates MR‑induced EGFR expression. In RNA‑sequencing and qPCR experiments in heart tissue of EGFR KO and WT mice, changes in EGFR abundance led to diferential expression of cardiac ion channels, especially of the T‑type calcium channel CACNA1H. Accordingly, CACNA1H expression was increased in WT mice after in vivo MR activation by aldosterone but not in respective EGFR KO mice. Aldosterone‑ and EGF‑responsiveness of CACNA1H expression was confrmed in HL‑1 cells by Western blot and by measuring peak current density of T‑type calcium channels. Aldosterone‑induced CACNA1H protein expression could be abrogated by the EGFR inhibitor AG1478. Furthermore, inhibition of T‑type calcium channels with mibefradil or ML218 reduced diameter, volume and BNP levels in HL‑1 cells. In conclusion the MR regulates EGFR and CACNA1H expression, which has an efect on HL‑1 cell diameter, and the extent of this regulation seems to depend on the SNP‑216 (G/T) genotype.
    [Show full text]
  • Rabbit Anti-CHRNA10/FITC Conjugated Antibody-SL12111R-FITC
    SunLong Biotech Co.,LTD Tel: 0086-571- 56623320 Fax:0086-571- 56623318 E-mail:[email protected] www.sunlongbiotech.com Rabbit Anti-CHRNA10/FITC Conjugated antibody SL12111R-FITC Product Name: Anti-CHRNA10/FITC Chinese Name: FITC标记的烟碱型乙酰胆碱受体α10/AChRα10抗体 Acetylcholine receptor, neuronal nicotinic, alpha-10 subunit; ACH10_HUMAN; Alpha 10 nAChR; Cholinergic receptor nicotinic alpha 10; Cholinergic receptor, neuronal nicotinic, alpha polypeptide 10; Cholinergic receptor, nicotinic, alpha polypeptide 10; Alias: CHRNA 10; CHRNA10; NACHR alpha 10; NACHR alpha-10; NACHRA10; Neuronal acetylcholine receptor protein subunit alpha 10; Neuronal acetylcholine receptor subunit alpha-10; Nicotinic acetylcholine receptor subunit alpha 10; Nicotinic acetylcholine receptor subunit alpha-10. Organism Species: Rabbit Clonality: Polyclonal React Species: Human,Mouse,Rat,Dog,Pig,Cow,Horse,Rabbit,Sheep, ICC=1:50-200IF=1:50-200 Applications: not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. Molecular weight: 47kDa Cellular localization: The cell membrane Form: Lyophilizedwww.sunlongbiotech.com or Liquid Concentration: 1mg/ml immunogen: KLH conjugated synthetic peptide derived from human CHRNA10 Lsotype: IgG Purification: affinity purified by Protein A Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year Storage: when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. background: Product Detail: Members of the ligand-gated ion channel receptor family are characterized by their fast transmitting response to neurotransmitters.
    [Show full text]
  • GJA4/Connexin 37 Mutations Correlate with Secondary Lymphedema Following Surgery in Breast Cancer Patients
    biomedicines Article GJA4/Connexin 37 Mutations Correlate with Secondary Lymphedema Following Surgery in Breast Cancer Patients Mahrooyeh Hadizadeh 1,2, Seiied Mojtaba Mohaddes Ardebili 1, Mansoor Salehi 2, Chris Young 3, Fariborz Mokarian 4, James McClellan 5, Qin Xu 6, Mohammad Kazemi 2, Elham Moazam 4, Behzad Mahaki 7 ID and Maziar Ashrafian Bonab 8,* 1 Department of Medical Genetics, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz 5166614766, Iran; [email protected] (M.H.); [email protected] (S.M.M.A.) 2 Department of Genetics and Molecular Biology, Isfahan University of Medical Sciences, Isfahan 81746753461, Iran; [email protected] (M.S.); [email protected] (M.K.) 3 School of Allied Health Sciences, Faculty of Health and Life Sciences, De Montfort University, Leicester LE1 9BH, UK; [email protected] 4 Cancer Prevention Research Centre, Isfahan University of Medical Sciences, Isfahan 8184917911, Iran; [email protected] (F.M.); [email protected] (E.M.) 5 School of Biological Sciences, University of Portsmouth, Portsmouth PO1 2DY, UK; [email protected] 6 School of Pharmacy, Faculty of Health and Life Sciences, De Montfort University, Leicester LE1 9BH, UK; [email protected] 7 Department of Occupational Health Engineering, School of Health, Isfahan University of Medical Sciences, Isfahan 8174673461, Iran; [email protected] 8 Department of Biological Sciences, University of Chester, Chester CH1 4BJ, UK * Correspondence: [email protected]; Tel.: +44-(0)1244-513-056 Received: 31 December 2017; Accepted: 13 February 2018; Published: 22 February 2018 Abstract: Lymphedema is a condition resulting from mutations in various genes essential for lymphatic development and function, which leads to obstruction of the lymphatic system.
    [Show full text]
  • Anti-GJA4 / Connexin 37 Antibody (ARG58815)
    Product datasheet [email protected] ARG58815 Package: 50 μg anti-GJA4 / Connexin 37 antibody Store at: -20°C Summary Product Description Rabbit Polyclonal antibody recognizes GJA4 / Connexin 37 Tested Reactivity Hu, Ms, Rat Predict Reactivity Hm Tested Application ICC, IHC-Fr, WB Host Rabbit Clonality Polyclonal Isotype IgG Target Name GJA4 / Connexin 37 Species Human Immunogen Synthetic peptide corresponding to aa. 3-17 of Human Connexin 37 (DWGFLEKLLDQVQEH). Conjugation Un-conjugated Alternate Names Connexin-37; Gap junction alpha-4 protein; CX37; Cx37 Application Instructions Application table Application Dilution ICC 0.5 - 1 µg/ml IHC-Fr 1:200 - 1:1000 WB 0.1 - 0.5 µg/ml Application Note * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. Properties Form Liquid Purification Affinity purification with immunogen. Buffer 0.9% NaCl, 0.2% Na2HPO4, 0.05% Thimerosal, 0.05% Sodium azide and 5% BSA. Preservative 0.05% Thimerosal and 0.05% Sodium azide Stabilizer 5% BSA Concentration 0.5 mg/ml Storage instruction For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C or below. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use. www.arigobio.com 1/3 Note For laboratory research only, not for drug, diagnostic or other use. Bioinformation Gene Symbol GJA4 Gene Full Name gap junction protein, alpha 4, 37kDa Background This gene encodes a member of the connexin gene family.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Transcriptomic Analysis of Native Versus Cultured Human and Mouse Dorsal Root Ganglia Focused on Pharmacological Targets Short
    bioRxiv preprint doi: https://doi.org/10.1101/766865; this version posted September 12, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. Transcriptomic analysis of native versus cultured human and mouse dorsal root ganglia focused on pharmacological targets Short title: Comparative transcriptomics of acutely dissected versus cultured DRGs Andi Wangzhou1, Lisa A. McIlvried2, Candler Paige1, Paulino Barragan-Iglesias1, Carolyn A. Guzman1, Gregory Dussor1, Pradipta R. Ray1,#, Robert W. Gereau IV2, # and Theodore J. Price1, # 1The University of Texas at Dallas, School of Behavioral and Brain Sciences and Center for Advanced Pain Studies, 800 W Campbell Rd. Richardson, TX, 75080, USA 2Washington University Pain Center and Department of Anesthesiology, Washington University School of Medicine # corresponding authors [email protected], [email protected] and [email protected] Funding: NIH grants T32DA007261 (LM); NS065926 and NS102161 (TJP); NS106953 and NS042595 (RWG). The authors declare no conflicts of interest Author Contributions Conceived of the Project: PRR, RWG IV and TJP Performed Experiments: AW, LAM, CP, PB-I Supervised Experiments: GD, RWG IV, TJP Analyzed Data: AW, LAM, CP, CAG, PRR Supervised Bioinformatics Analysis: PRR Drew Figures: AW, PRR Wrote and Edited Manuscript: AW, LAM, CP, GD, PRR, RWG IV, TJP All authors approved the final version of the manuscript. 1 bioRxiv preprint doi: https://doi.org/10.1101/766865; this version posted September 12, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
    [Show full text]
  • Targeting Lysophosphatidic Acid in Cancer: the Issues in Moving from Bench to Bedside
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by IUPUIScholarWorks cancers Review Targeting Lysophosphatidic Acid in Cancer: The Issues in Moving from Bench to Bedside Yan Xu Department of Obstetrics and Gynecology, Indiana University School of Medicine, 950 W. Walnut Street R2-E380, Indianapolis, IN 46202, USA; [email protected]; Tel.: +1-317-274-3972 Received: 28 August 2019; Accepted: 8 October 2019; Published: 10 October 2019 Abstract: Since the clear demonstration of lysophosphatidic acid (LPA)’s pathological roles in cancer in the mid-1990s, more than 1000 papers relating LPA to various types of cancer were published. Through these studies, LPA was established as a target for cancer. Although LPA-related inhibitors entered clinical trials for fibrosis, the concept of targeting LPA is yet to be moved to clinical cancer treatment. The major challenges that we are facing in moving LPA application from bench to bedside include the intrinsic and complicated metabolic, functional, and signaling properties of LPA, as well as technical issues, which are discussed in this review. Potential strategies and perspectives to improve the translational progress are suggested. Despite these challenges, we are optimistic that LPA blockage, particularly in combination with other agents, is on the horizon to be incorporated into clinical applications. Keywords: Autotaxin (ATX); ovarian cancer (OC); cancer stem cell (CSC); electrospray ionization tandem mass spectrometry (ESI-MS/MS); G-protein coupled receptor (GPCR); lipid phosphate phosphatase enzymes (LPPs); lysophosphatidic acid (LPA); phospholipase A2 enzymes (PLA2s); nuclear receptor peroxisome proliferator-activated receptor (PPAR); sphingosine-1 phosphate (S1P) 1.
    [Show full text]
  • Patient-Based Cross-Platform Comparison of Oligonucleotide Microarray Expression Profiles
    Laboratory Investigation (2005) 85, 1024–1039 & 2005 USCAP, Inc All rights reserved 0023-6837/05 $30.00 www.laboratoryinvestigation.org Patient-based cross-platform comparison of oligonucleotide microarray expression profiles Joerg Schlingemann1,*, Negusse Habtemichael2,*, Carina Ittrich3, Grischa Toedt1, Heidi Kramer1, Markus Hambek4, Rainald Knecht4, Peter Lichter1, Roland Stauber2 and Meinhard Hahn1 1Division of Molecular Genetics, Deutsches Krebsforschungszentrum, Heidelberg, Germany; 2Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus, Frankfurt am Main, Germany; 3Central Unit Biostatistics, Deutsches Krebsforschungszentrum, Heidelberg, Germany and 4Department of Otorhinolaryngology, Universita¨tsklinik, Johann-Wolfgang-Goethe-Universita¨t Frankfurt, Frankfurt, Germany The comparison of gene expression measurements obtained with different technical approaches is of substantial interest in order to clarify whether interplatform differences may conceal biologically significant information. To address this concern, we analyzed gene expression in a set of head and neck squamous cell carcinoma patients, using both spotted oligonucleotide microarrays made from a large collection of 70-mer probes and commercial arrays produced by in situ synthesis of sets of multiple 25-mer oligonucleotides per gene. Expression measurements were compared for 4425 genes represented on both platforms, which revealed strong correlations between the corresponding data sets. Of note, a global tendency towards smaller absolute ratios was observed when
    [Show full text]
  • Cdk15 Igfals Lingo4 Gjb3 Tpbg Lrrc38 Serpinf1 Apod Trp73 Lama4 Chrnd Col9a1col11a1col5a2 Fgl2 Pitx2 Col2a1 Col3a1 Lamb3 Col24a1
    Bnc2 Wdr72 Ptchd1 Abtb2 Spag5 Zfp385a Trim17 Ier2 Il1rapl1 Tpd52l1 Fam20a Car8 Syt5 Plxnc1 Sema3e Ndrg4 Snph St6galnac5 Mcpt2 B3galt2 Sphkap Arhgap24 Prss34 Lhfpl2 Ermap Rnf165 Shroom1 Grm4 Mobp Dock2 Tmem9b Slc35d3 Otud7b Serpinb3a Sh3d19 Syt6 Zan Trim67 Clec18a Mcoln1 Tob1 Slc45a2 Pcdhb9 Pcdh17 Plscr1 Gpr143 Cela1 Frem1 Sema3f Lgi2 Igsf9 Fjx1 Cpne4 Adgb Depdc7 Gzmm C1qtnf5 Capn11 Sema3c H2-T22 Unc5c Sytl4 Galnt5 Sytl2 Arhgap11a Pcdha1 Cdh20 Slc35f2 Trim29 B3gnt5 Dock5 Trim9 Padi4 Pcdh19 Abi2 Cldn11 Slitrk1 Fam13a Nrgn Cpa4 Clmp Il1rap Trpm1 Fat4 Nexn Pmel Mmp15 Fat3 H2-M5 Prss38 Wdr41 Prtg Mlana Mettl22 Tnrc6b Cdh6 Sema3b Ptgfrn Cldn1 Cntn4 Bcl2a1b Capn6 Capn5 Pcdhb19 Tcf15 Bmf Rgs8 Tecrl Tyrp1 Rhot1 Rnf123 Cldn6 Adam9 Hlx Rilpl1 Disp1 Atcay Vwc2 Fat2 Srpx2 Cldn3 Unc13c Creb3l1 Rab39b Robo3 Gpnmb Bves Orai2 Slc22a2 Prss8 Cdh10 Scg3 Adam33 Nyx Dchs1 Chmp4c Syt9 Ap1m2 Megf10 Cthrc1 Penk Igsf9b Akap2 Ltbp3 Dnmbp Tff2 Pnoc Vldlr Cpa3 Snx18 Capn3 Btla Htr1b Gm17231 Pcdh9Rab27a Grm8 Cnih2 Scube2 Id2 Reep1 Cpeb3 Mmp16 Slc18b1 Snx33 Clcn5 Cckbr Pkp2 Drp2 Mapk8ip1 Lrrc3b Cxcl14 Zfhx3 Esrp1 Prx Dock3 Sec14l1 Prokr1 Pstpip2 Usp2 Cpvl Syn2 Ntn1 Ptger1 Rxfp3 Tyr Snap91 Htr1d Mtnr1a Gadd45g Mlph Drd4 Foxc2 Cldn4 Birc7 Cdh17 Twist2 Scnn1b Abcc4 Pkp1 Dlk2 Rab3b Amph Mreg Il33 Slit2 Hpse Micu1 Creb3l2 Dsp Lifr S1pr5 Krt15 Svep1 Ahnak Kcnh1 Sphk1 Vwce Clcf1 Ptch2 Pmp22 Sfrp1 Sema6a Lfng Hs3st5 Efcab1 Tlr5 Muc5acKalrn Vwa2 Fzd8 Lpar6 Bmp5 Slc16a9 Cacng4 Arvcf Igfbp2 Mrvi1 Dusp15 Krt5 Atp13a5 Dsg1a Kcnj14 Edn3Memo1 Ngef Prickle2 Cma1 Alx4 Bmp3 Blnk GastAgtr2
    [Show full text]